Related Experiment Video
Updated: Aug 5, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
Diet Quality and Micronutrient Intake among United States Adults Eligible for GLP-1 Receptor Agonist Antiobesity
Demsina Babazadeh1, Huimin Zhong2, Francene M Steinberg1
1Department of Nutrition, Graduate Group in Nutritional Biology, University of California, Davis, CA, United States; Department of Nutrition, University of California, Davis, CA, United States.
Background:
Glucagon-like peptide-1 receptor agonist antiobesity medications (GLP-1 RA AOMs) are increasingly prescribed for obesity management; however, baseline dietary quality and nutritional risk among treatment-eligible populations remain poorly characterized.
Objectives:
We aimed to compare diet quality and micronutrient adequacy among United States adults meeting GLP-1 RA AOM eligibility criteria and examine whether differences persist after accounting for sociodemographic, behavioral, and clinical factors.
Methods:
We conducted a cross-sectional analysis of adults aged ≥20 y from the National Health and Nutrition Examination Survey 2005-2020. GLP-1 RA AOM eligibility was defined according to prescribing criteria [body mass index (BMI) ≥30 kg/m2 or BMI ≥27 kg/m2 with ≥1 obesity-related comorbidity]. Diet quality was assessed using Healthy Eating Index-2025 (HEI-2015) from 24-h dietary recalls. Micronutrient inadequacy was evaluated relative to estimated average requirements and adequate intake benchmarks. Survey-weighted linear regression models adjusted for demographic, socioeconomic, behavioral, and clinical covariates. Stratified analyses examined BMI class and food security.
Results:
Among 16,143 adults (representing 97.7 million United States adults), 43.5% (95% confidence interval: 42.6%, 44.5%) met GLP-1 RA AOM eligibility criteria. Eligible adults had poorer diet quality than noneligible adults (HEI-2015: 49.2 compared with 51.7; P < 0.001), corresponding to an unadjusted difference of -2.50 points. Differences persisted after demographic (β = -2.19) and socioeconomic adjustment (β = -2.05) but were substantially attenuated and no longer statistically significant after additional adjustment for waist circumference (β = -0.42; P = 0.29), suggesting that central adiposity was strongly associated with the observed association between GLP-1 RA AOM eligibility and diet quality. Component analyses showed poorer scores for nutrient-dense foods, including fruits, vegetables, whole grains, and plant proteins. Higher waist circumference was independently associated with poorer diet quality (β = -1.47 HEI points per quartile). Micronutrient inadequacy was modestly higher among eligible adults for several nutrients, including vitamin C, vitamin A, magnesium, vitamin E, vitamin D, fiber, potassium, and vitamin K.
Conclusions:
Adults eligible for GLP-1 RA AOM therapy demonstrate modest but consistent differences in baseline diet quality and micronutrient adequacy. These findings suggest that modest nutrition risk may co-occur with GLP-1 RA AOM eligibility and support consideration of nutrition assessment as part of comprehensive obesity care.
Related Concept Videos
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug Dosing: Obese Patients